GENERAL COMMENTS
The current paper reports the protocol of cohort study on long-term sequelae of sepsis survivors. Although it becomes fashionable to report protocols of ongoing studies, I am quite skeptical whether those paper deserved publication. Except of this I have no further comments on the current paper. The study design is well described and I am probably not asked to judge on the design. Some minor comments: It is stated that 3,000 patients will be included over 3 years. However, I am missing the number of patients that are treated in hospitals and whether the number is realistic or not. What will be done if the number is reached earlier or not reached at all? While line 4 says that no exclusion criteria are applied, line 24 gives criteria for the eligibility of the inclusion. Sample size calculation is well done. In the chapter "Ethics and Dissemination" some comments on the data protection issues could be helpful. All other sentences in this page are quite standard and not specific to this study (so they could all be deleted as they do not add any important news).
I recommend to publish the paper according to your rules of publishing protocols.
REVIEWER

John Marshall
St. Michael's Hospital University of Toronto Canada I am an advisor to the Jena Center for Sepsis Control and Care, the sponsoring center of the planned study.
REVIEW RETURNED
25-Apr-2017
GENERAL COMMENTS General Comments
This ,manuscript describes a protocol for a cohort study of ICU survivors of sepsis, undertaken to better understand intermediate and long term morbidity to inform the design of future supportive and therapeutic interventions. Data will be collected from 3000 survivors admitted to one of 5 German hospitals.
The proposal focuses on an important and inadequately studied aspect of sepsis -the long term burden of illness in survivors. It would be improved by a more rigourous and informed approach to measuring these, and the investigators are strongly urged to collaborate with other groups having an interest in this underdeveloped area to ensure that the results are methodologically robust and relevant to the needs of patients.
Specific Comments
1.
The consent model that you will be using to recruit sepsis survivors is not well-described; please provide more detail. One would anticipate that most subjects who survive their hospital stay can provide first party consent.
2.
Long term outcome measures relevant to sepsis survivorship are poorly understood, and of questionable value in detecting key deficits. I would suggest that you liaise with other experts in the field to ensure that these are the best available, particularly Dale Needham (Johns Hopkins) and Margaret Herridge (University of Toronto). The list of outcomes (Table 2) seems incompletely thought out, yet is critical to the conclusions of your project.
3.
Followup is with either the survivor or a surrogate decisionmaker; these groups are likely to have quite differing perspectives on survivor function. Do you plan separate analyses? Will you evaluate both when possible to understand how perspective on outcomes differs?
4.
The specific hypotheses and analytic plan are underdeveloped. You will acquire descriptive data, but do you plan to relate longer term morbidity to modifiable or non-modifiable factors during the acute illness?
5.
The interpretation of outcome data such as those to be collected here is dependent upon the control group selected. What is your control population, and how will you control for the increased rate of baseline co-morbidities likely to be present in a population of ICU survivors?
VERSION 1 -AUTHOR RESPONSE
Reviewer# 1: Hallie Prescott
This is a clearly written protocol for an important study. I have no concerns.
Answer: Thank you very much.
Reviewer#2: Prof. Dr. Maria Blettner
The current paper reports the protocol of cohort study on long-term sequelae of sepsis survivors. Although it becomes fashionable to report protocols of ongoing studies, I am quite skeptical whether those paper deserved publication. Except of this I have no further comments on the current paper. The study design is well described and I am probably not asked to judge on the design.
Some minor comments:
It is stated that 3,000 patients will be included over 3 years. However, I am missing the number of patients that are treated in hospitals and whether the number is realistic or not. What will be done if the number is reached earlier or not reached at all?
Answer: In 2011 and 2012, 777 ICU patients with (severe) sepsis and septic shock were prospectively enrolled in the CSCC Jena Sepsis Registry (Schmidt et al, 2013). ICU mortality was 32% (95%CI [29%;35%]), hospital mortality 45% (95%CI [42%;50%]), 6-month mortality was 62% (95%CI [58%;65%]), and 12-month mortality was 67% (95%CI [63%;70%]).
Therefore, about 350-400 patients with (severe) sepsis and septic shock can be assumed to be treated per year on the ICUs at the Jena University Hospital (JUH). Extrapolating the JUH numbers to four centers with an approximately equal number of patients on their ICUs, the recruitment of about 1,000 patients per year seems feasible. Thus, to recruit 3,000 ICU-treated patients with (severe) sepsis and septic shock within a recruitment period of 3 years seems realizable. Approximately 40% will survive the first 6 months after ICU discharge and ~30% (i.e. about 1,000 patients) will survive the first 12 months.
In reality, there are already about 1,000 patients included after one year of recruitment (04/2017). Note that numbers will likely be better in the future given the delayed start of the other centers.
In case the number will be reached earlier, recruitment will be stopped early and all forces will be focused on the follow-up. In case the number will not be reached we are allowed to extent the recruitment time to some extent (~0.5 year) as we pay the centers a case money (and are now allowed to shift some of the money longitudinally).
While line 4 says that no exclusion criteria are applied, line 24 gives criteria for the eligibility of the inclusion. Sample size calculation is well done.
Answer: Eligibility criteria need some clarification and we change the wording to "minimal exclusion criteria". Of course inclusion is limited to adult (≥ 18 years at ICU discharge) ICU-treated patients with (severe) sepsis and septic shock. In contrast to other patient cohorts, exclusion criteria are limited to a prior MSC enrollment only. However, this only applies to the ICU assessments. For the follow-up interviews, patients or their proxies who are not fluent in German also had to be excluded (as there was no funding for translating the CRFs to multiple languages or for employing multilingual interviewers; translating everything to English would have been no solution due to the multilingual background of some of the patients).
In the chapter "Ethics and Dissemination" some comments on the data protection issues could be helpful. All other sentences in this page are quite standard and not specific to this study (so they could all be deleted as they do not add any important news).
Answer: We deleted some standard descriptions, extended the part on informed consent for reviewer#3 and shifted some of the data protection descriptions to this chapter.
Reviewer#3: John Marshall
This ,manuscript describes a protocol for a cohort study of ICU survivors of sepsis, undertaken to better understand intermediate and long term morbidity to inform the design of future supportive and therapeutic interventions. Data will be collected from 3000 survivors admitted to one of 5 German hospitals. The proposal focuses on an important and inadequately studied aspect of sepsis -the long term burden of illness in survivors. It would be improved by a more rigourous and informed approach to measuring these, and the investigators are strongly urged to collaborate with other groups having an interest in this under-developed area to ensure that the results are methodologically robust and relevant to the needs of patients.
1.
Answer: Indeed this aspect requires more detail. First of all we would like to underline that consenting is limited to the follow-up. Study nurses who screen for (severe) sepsis and septic shock at ICUs are located at the ICUs and only doctors are allowed to do the consenting. In case patients move to normal wards and no consent has been obtained at the ICU, getting the consent is quite challenging (as this implies that doctors have to move to a foreign ward). In the other case of a patient not being able to provide consent herself/himself, her/his legal representative is asked for the consent. If this option doesn't work either, we are allowed to approach a family member asking her/him if we are allowed to contact the patient later by telephone (when she/he is back home) in order to ask the patient for her/his consent. This rather complicated work-flow has been worked out with data protection officers and is also fine with institutional ethics committees.
We have extended the respective text in the manuscript:
"No informed consent is required to collect routine documentation of acute care (T0, T1, and T2). Local study physicians obtain written informed consent for follow-up interviews from eligible patients (or their legal proxies) during the ICU or subsequent hospital stay. Patients or proxies are provided with written information about study aims and funding, study design and follow-up intervals, approximate duration of interviews, data protection and IRB approval. Patients are assured that participation is voluntary, can be withdrawn at any time and that refusal to participate has no impact on medical treatment. If no legal proxy was established and written informed consent cannot be obtained during the acute hospital stay, family members receive a brochure with detailed information about the MSC and are kindly asked to provide consent that the patient's contact information may be forwarded to the study center so that the patient may be contacted later to obtain informed consent."
2.
Answer: Thank you the opportunity to clarify. We extended the text accordingly:
"A comprehensive list of physical, functional, emotional and mental sepsis outcomes documented at the follow-up appointments (FU1, FU2, FU3, etc.) was put together by the use of several sources (see Table 2 for an overview): We performed a comprehensive literature search and used instruments of the German National Cohort [12] . In addition, we drew on other CSCC post-acute experiences (e.g. [13, 14] ) and refined the list by obtaining feedback from sepsis survivors and relatives from the German Sepsis Aid [15] who advised on the comprehensiveness as well as relevance and also translated the final list of symptoms into lay terms (for instance, "tingling" for paresthesia, "weakness of memory" or "difficulty to concentrate" for cognitive impairments, etc.). These lay terms are also used during the follow-up interview. We were also advised by Wes Ely (Vanderbilt University School of Medicine, Nashville, USA) on delirium monitoring and management in the ICU and assessment of pre-ICU cognitive functioning. All outcomes -except for hearing, tasting, smelling and swallowingare measured by established and validated questionnaires. [25] is used for assessment of the HRQOL prior to and after sepsis. Furthermore, survival status and other more specific domains of morbidity (e.g. effects on tasting or sleeping), and health care utilization as well as socio-economic effects and reintegration after sepsis are documented. Readmissions to hospitals, recurrent sepsis episodes, occurrence of infections, data on immunization habits and persistence of multi-resistant infections are recorded. We aim for face-to-face contacts at least once during the study period and assess, to assess the timed-up and go test [26] and hand grip strength [27] . We developed a written interview guide and refined the interview during a pilot test."
